Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324868 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25180667 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8957343 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1842696 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25180691 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL25184217 | 1.00 | CA12 (0.50) | CA12CA1CA2CA4CA9 | |
| Ammonia Solution, Strong SCHEMBL9446994 | 0.97 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| Ammonia Solution, Strong SCHEMBL6736966 | 0.97 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1220763 | 0.97 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4731008 | 0.90 | CA12 (0.48) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | DSM IP ASSETS B.V. (NL) | 2026-04-28 | — | — | US | disclosed |
| US-12522558-B2 | Process for the acylation of an alpha, omega-alkanediol | DSM IP ASSETS B.V. (CH) | 2026-01-13 | — | — | US | disclosed |
| EP-4139279-B1 | PROCESS FOR THE ACYLATION OF AN ALPHA,OMEGA-ALKANEDIOL | DSM IP ASSETS BV (NL) | 2024-04-17 | — | — | EP | disclosed |
| US-20230167047-A1 | PROCESS FOR THE ACYLATION OF AN ALPHA, OMEGA-ALKANDIOL | DSM IP ASSETS B.V. (NL) | 2023-06-01 | — | — | US | disclosed |
| US-20230167048-A1 | PROCESS FOR THE PREPARATION OF OMEGA-ALKANEDIOL MONONITRATE | DSM IP ASSETS B.V. (NL) | 2023-06-01 | — | — | US | disclosed |
| US-20230150917-A1 | PROCESS FOR THE PREPARATION OF ALPHA,OMEGA-ALKANEDIOL MONONITRATE | DSM IP ASSETS B.V. (NL) | 2023-05-18 | — | — | US | disclosed |
| US-20230150916-A1 | PROCESS FOR NITRATE ESTER FORMATION OF AN ALPHA,OMEGA-ALKANEDIOL MONOACYLATE | DSM IP ASSETS B.V. (NL) | 2023-05-18 | — | — | US | disclosed |
| EP-4139277-A1 | PROCESS FOR THE PREPARATION OF ALPHA,OMEGA-ALKANEDIOL MONONITRATE | DSM IP Assets B.V. (NL) | 2023-03-01 | — | — | EP | disclosed |
| EP-4139278-A1 | PROCESS FOR NITRATE ESTER FORMATION OF AN ALPHA,OMEGA-ALKANEDIOL MONOACYLATE | DSM IP Assets B.V. (NL) | 2023-03-01 | — | — | EP | disclosed |
| EP-4139279-A1 | PROCESS FOR THE ACYLATION OF AN ALPHA, OMEGA-ALKANEDIOL | DSM IP Assets B.V. (NL) | 2023-03-01 | — | — | EP | disclosed |
| EP-4139276-A1 | PROCESS FOR THE PREPARATION OF OMEGA-ALKANEDIOL MONONITRATE | DSM IP Assets B.V. (NL) | 2023-03-01 | — | — | EP | disclosed |
| CN-115461321-A | Process for preparing alpha, omega-alkanediol mononitrate | 帝斯曼知识产权资产管理有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115443263-A | Process for acylating alpha, omega-alkanediols | 帝斯曼知识产权资产管理有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115427389-A | Process for the preparation of omega-alkanediol mononitrate | 帝斯曼知识产权资产管理有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-115427390-A | Method for nitrate ester formation of alpha, omega-alkanediol monoacylates | 帝斯曼知识产权资产管理有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20130160354-A1 | ORGANIC NITRATES AS IGNITION ENHANCERS | SHELL OIL COMPANY (US) | 2013-06-27 | — | — | US | disclosed |
| EP-0689435-A1 | USE OF SUBSTITUTED ALKYL NITRATES FOR THE TREATMENT OF PATHOLOGICALLY INCREASED INTRA-OCULAR PRESSURE | BYK NEDERLAND BV (NL) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021248-A1 | USE OF SUBSTITUTED ALKYL NITRATES FOR THE TREATMENT OF PATHOLOGICALLY INCREASED INTRA-OCULAR PRESSURE | BYK NEDERLAND BV (NL) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | ELOVL3, ELOVL1, PTGES | CA12 1956/4885CA1 2237/4885CA2 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.